Ausgabe 11/2023
Special Issue: Therapy of Advanced Parkinson´s Disease: Long Neglected, Now in Focus
Inhalt (16 Artikel)
If you can't be with the one you love, love the one you're with (C, S, N & Y)
Wolfgang H. Jost
L-DOPA-therapy in Parkinson’s disease: some personal reflections on L-DOPA therapy from Vienna and Berlin
Peter Riederer, Reinhard Horowski
Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson’s disease
P. Jenner, C. Falup-Pecurariu, V. Leta, M. Verin, M. Auffret, Roongroj Bhidayasiri, D. Weiss, F. Borovečki, W. H. Jost
Current and novel infusion therapies for patients with Parkinson's disease
Angelo Antonini, Valentina D’Onofrio, Andrea Guerra
Tools and criteria to select patients with advanced Parkinson’s disease for device-aided therapies: a narrative review
Harmen R. Moes, Tove Henriksen, Jarosław Sławek, Onanong Phokaewvarangkul, Erik Buskens, Teus van Laar
Apprends-moi l'art des petits pas: Levodopa, Carbidopa Intestinal Gel plus Entacapone
Wolfgang H. Jost
Optimised endoscopic access for intrajejunal levodopa application in idiopathic Parkinson's syndrome
K. E. Grund, A. Zipfel, B. Duckworth-Mothes, W. H. Jost
Should continuous dopaminergic stimulation be a standard of care in advanced Parkinson’s disease?
Z. Pirtošek, V. Leta, P. Jenner, M. Vérin
Are Parkinson’s disease patients referred too late for device-aided therapies and how can better informed and earlier referrals be encouraged?
Fran Borovečki, Romana Perković, Norbert Kovacs, Peter A. LeWitt, Monika Rudzinska Bar, Regina Katzenschlager
Access to device-aided therapies in advanced Parkinson’s disease: navigating clinician biases, patient preference, and prognostic uncertainty
Manon Auffret, Daniel Weiss, Fabrizio Stocchi, Marc Vérin, Wolfgang H. Jost
Towards improved access to device-aided therapies in advanced PD: the importance of cooperation of different disciplines
Jaime Kulisevsky, Cristian Falup-Pecurariu, Patrick Santens, Wolfgang H. Jost
Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease
P. Tall, M. A. Qamar, L. Batzu, V. Leta, C. Falup-Pecurariu, K. Ray Chaudhuri
Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson’s disease: clinical and therapeutic considerations
Onanong Phokaewvarangkul, Roongroj Bhidayasiri, Pedro Garcia-Ruiz, Per Odin, Peter Riederer, Thomas Müller
Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson’s disease: the APOKADO study
Fabien Zagnoli, Amélie Leblanc, Irina Viakhireva-Dovganyuk, Jean-Philippe Delabrousse-Mayoux, Alain Pouyet, Marc Ziegler, Laura Sogni, Marie Patat, Régis Bouillot, Marc Vérin, Andrei Arhire, Philippe Barres, Maxime Blondiaux, Jean-Claude Bouffeteau, Jean-Philippe Brandel, Christophe Carel, Giovanni Castelnovo, Marc Coustans, Lucie Courault, Christian Crauser, Isabelle Degaey, Bertrand Degos, Jean-Philippe Delabrousse, Béatrice Denis, Marie-Claude Dourneau, Arnaud Duretete, Jean-Marc François Feve, Erika Follin, Michel Gugenheim, Cécile Hubsch, Nathalie Patte Karsenti, Pierre Louchart, Serge Massengo, José Mejias, Homero Monteiro, Philippe Muh, Bernard Pedespan, Virginie Sattler, Mathieu Sevin, Mélissa Tir, Anne Tirel Badets, Marc Verin, Irina Viakhireva, Elisabeth Vidry, Jean-Charles Wiart
Practical use of apomorphine infusion in Parkinson’s disease: lessons from the TOLEDO study and clinical experience
Tove Henriksen, Regina Katzenschlager, Roongroj Bhidayasiri, Harry Staines, Donna Lockhart, Andrew Lees
Home initiation of apomorphine infusion: lessons from the COVID-19 pandemic and implications for current clinical practice
Christopher Kobylecki, Lucy Partington-Smith